A team of researchers from Swansea University in Wales has developed a new blood test that can detect bowel cancer earlier.

The Raman Spectrometry (RS) blood test delivered promising results in a primary care trial. It identified around 79% of early-stage bowel cancers and 100% of advanced bowel cancers in a study that involved 27 practices and 595 patients across West Wales.

Initial data indicated that the blood test has greater sensitivity for the detection of bowel cancer compared to other similar tests currently available in primary care.

The development of the RS blood test was funded by Cancer Research Wales along with Health and Care Research Wales.

A Welsh start-up business, CanSense, has now secured support from Life Sciences Hub Wales and an additional £1.2m commitment from the National Institute for Health and Care Research (NIHR) to further develop the technology, which would facilitate the clinical adoption of the test across Wales.

The start-up will seek to deliver a test that will offer results in 48 hours.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

It is expected that the introduction of the test will reduce diagnosis wait times, eliminate the need for unnecessary invasive procedures, such as colonoscopies, and reduce pressure on the NHS.

CanSense co-founder and director Dr Cerys Jenkins said: “The goal for this research has always been to translate it into something that fits into the existing patient pathway.

“Having this test available at the triage stage would save time, money, but most importantly save the patients from anxiety and unnecessary diagnostic tests.”

Every year, 2,200 people are diagnosed with bowel cancer in Wales, with most diagnoses occurring at an advanced stage. It is the second leading cause of cancer death in Wales.